S&P 500   3,757.94 (-0.67%)
DOW   30,008.77 (-0.88%)
QQQ   281.90 (-0.03%)
AAPL   146.46 (+0.04%)
MSFT   248.36 (-0.34%)
META   141.20 (+1.60%)
GOOGL   102.16 (+0.72%)
AMZN   120.88 (-0.06%)
TSLA   241.77 (+0.40%)
NVDA   133.32 (+0.93%)
NIO   14.97 (-6.67%)
BABA   85.03 (+0.76%)
AMD   68.88 (+1.38%)
T   15.46 (-2.95%)
MU   54.82 (+0.16%)
CGC   2.98 (-2.93%)
F   12.47 (-0.32%)
GE   66.25 (-1.76%)
DIS   101.06 (+0.26%)
AMC   7.34 (+0.14%)
PYPL   94.81 (+1.04%)
PFE   43.31 (-1.84%)
NFLX   242.66 (+2.50%)
S&P 500   3,757.94 (-0.67%)
DOW   30,008.77 (-0.88%)
QQQ   281.90 (-0.03%)
AAPL   146.46 (+0.04%)
MSFT   248.36 (-0.34%)
META   141.20 (+1.60%)
GOOGL   102.16 (+0.72%)
AMZN   120.88 (-0.06%)
TSLA   241.77 (+0.40%)
NVDA   133.32 (+0.93%)
NIO   14.97 (-6.67%)
BABA   85.03 (+0.76%)
AMD   68.88 (+1.38%)
T   15.46 (-2.95%)
MU   54.82 (+0.16%)
CGC   2.98 (-2.93%)
F   12.47 (-0.32%)
GE   66.25 (-1.76%)
DIS   101.06 (+0.26%)
AMC   7.34 (+0.14%)
PYPL   94.81 (+1.04%)
PFE   43.31 (-1.84%)
NFLX   242.66 (+2.50%)
S&P 500   3,757.94 (-0.67%)
DOW   30,008.77 (-0.88%)
QQQ   281.90 (-0.03%)
AAPL   146.46 (+0.04%)
MSFT   248.36 (-0.34%)
META   141.20 (+1.60%)
GOOGL   102.16 (+0.72%)
AMZN   120.88 (-0.06%)
TSLA   241.77 (+0.40%)
NVDA   133.32 (+0.93%)
NIO   14.97 (-6.67%)
BABA   85.03 (+0.76%)
AMD   68.88 (+1.38%)
T   15.46 (-2.95%)
MU   54.82 (+0.16%)
CGC   2.98 (-2.93%)
F   12.47 (-0.32%)
GE   66.25 (-1.76%)
DIS   101.06 (+0.26%)
AMC   7.34 (+0.14%)
PYPL   94.81 (+1.04%)
PFE   43.31 (-1.84%)
NFLX   242.66 (+2.50%)
S&P 500   3,757.94 (-0.67%)
DOW   30,008.77 (-0.88%)
QQQ   281.90 (-0.03%)
AAPL   146.46 (+0.04%)
MSFT   248.36 (-0.34%)
META   141.20 (+1.60%)
GOOGL   102.16 (+0.72%)
AMZN   120.88 (-0.06%)
TSLA   241.77 (+0.40%)
NVDA   133.32 (+0.93%)
NIO   14.97 (-6.67%)
BABA   85.03 (+0.76%)
AMD   68.88 (+1.38%)
T   15.46 (-2.95%)
MU   54.82 (+0.16%)
CGC   2.98 (-2.93%)
F   12.47 (-0.32%)
GE   66.25 (-1.76%)
DIS   101.06 (+0.26%)
AMC   7.34 (+0.14%)
PYPL   94.81 (+1.04%)
PFE   43.31 (-1.84%)
NFLX   242.66 (+2.50%)
NASDAQ:AMTX

Aemetis - AMTX Stock Forecast, Price & News

$6.96
+0.30 (+4.50%)
(As of 10/6/2022 01:57 PM ET)
Add
Compare
Today's Range
$6.66
$7.16
50-Day Range
$6.12
$11.12
52-Week Range
$4.45
$23.33
Volume
27,811 shs
Average Volume
578,306 shs
Market Capitalization
$240.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

Aemetis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
254.0% Upside
$24.00 Price Target
Short Interest
Bearish
17.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Aemetis in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.61) to ($0.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Oils/Energy Sector

178th out of 250 stocks

Industrial Organic Chemicals Industry

17th out of 20 stocks

AMTX stock logo

About Aemetis (NASDAQ:AMTX) Stock

Aemetis, Inc. operates as a renewable natural gas and renewable fuels company in North America and India. It operates through three segments: California Ethanol, Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products. It sells biodiesel primarily to government oil marketing companies, transport companies, resellers, distributors, and private refiners through its own sales force and independent sales agents, as well as to brokers who resell the product to end-users. The company also produces and sells ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. In addition, it produces dairy biogas; produces and sells high-grade alcohol and various feed products, as well as hand sanitizers; and researches and develops conversion technologies using waste feedstocks to produce biofuels and biochemicals. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.

Receive AMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aemetis and its competitors with MarketBeat's FREE daily newsletter.

AMTX Stock News Headlines

Aemetis, Inc.'s (NASDAQ:AMTX) Shift From Loss To Profit
See More Headlines
Receive AMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aemetis and its competitors with MarketBeat's FREE daily newsletter.

AMTX Company Calendar

Last Earnings
8/04/2022
Today
10/06/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:AMTX
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+244.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-47,150,000.00
Pretax Margin
-15.98%

Debt

Sales & Book Value

Annual Sales
$211.95 million
Book Value
($3.62) per share

Miscellaneous

Free Float
29,625,000
Market Cap
$240.68 million
Optionable
Not Optionable
Beta
0.79

Key Executives

  • Mr. Eric A. McAfee (Age 59)
    Co-Founder, Exec. Chairman & CEO
    Comp: $410k
  • Mr. Todd A. WaltzMr. Todd A. Waltz (Age 61)
    Exec. VP, CFO & Sec.
    Comp: $335k
  • Mr. Andrew B. FosterMr. Andrew B. Foster (Age 57)
    Exec. VP & COO
    Comp: $326.94k
  • Mr. Sanjeev  GuptaMr. Sanjeev Gupta (Age 62)
    Exec. VP
    Comp: $341.14k













AMTX Stock - Frequently Asked Questions

Should I buy or sell Aemetis stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMTX shares.
View AMTX analyst ratings
or view top-rated stocks.

What is Aemetis' stock price forecast for 2022?

3 brokers have issued 12 month price targets for Aemetis' shares. Their AMTX share price forecasts range from $12.00 to $33.00. On average, they predict the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 254.0% from the stock's current price.
View analysts price targets for AMTX
or view top-rated stocks among Wall Street analysts.

How have AMTX shares performed in 2022?

Aemetis' stock was trading at $12.30 at the start of the year. Since then, AMTX stock has decreased by 44.9% and is now trading at $6.78.
View the best growth stocks for 2022 here
.

When is Aemetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our AMTX earnings forecast
.

How were Aemetis' earnings last quarter?

Aemetis, Inc. (NASDAQ:AMTX) released its quarterly earnings results on Thursday, August, 4th. The specialty chemicals company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.40. The specialty chemicals company had revenue of $65.90 million for the quarter, compared to analyst estimates of $61.73 million. During the same period last year, the company earned ($0.38) EPS.

What other stocks do shareholders of Aemetis own?
What is Aemetis' stock symbol?

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

How do I buy shares of Aemetis?

Shares of AMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aemetis' stock price today?

One share of AMTX stock can currently be purchased for approximately $6.78.

How much money does Aemetis make?

Aemetis (NASDAQ:AMTX) has a market capitalization of $234.45 million and generates $211.95 million in revenue each year. The specialty chemicals company earns $-47,150,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How many employees does Aemetis have?

The company employs 158 workers across the globe.

How can I contact Aemetis?

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The official website for the company is www.aemetis.com. The specialty chemicals company can be reached via phone at (408) 213-0940, via email at investors@aemetis.com, or via fax at 408-252-8044.

This page (NASDAQ:AMTX) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.